Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...
As of Friday, February 27, Fulgent Genetics, Inc.’s FLGT share price has dipped by 31.34%, which has investors questioning if this is right time to buy.
Rare disease is a major – and growing – area of clinical research and drug development. Of the FDA’s 46 novel drug approvals ...
Plants are constantly exposed to a wide array of biotic and abiotic stresses in their natural environments, posing ...
Art and music classrooms are built on something AI will never fully replicate: the deeply personal act of creating something ...
As the climate crisis intensifies, traditional genetic breeding alone may not keep pace with the rapid shifts in environmental stressors. While the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results